AS-OCT Guided Treatment of Diffuse CSCC
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03515954|
Recruitment Status : Completed
First Posted : May 4, 2018
Last Update Posted : January 2, 2019
Information provided by (Responsible Party):
Tarek Roshdy mohamed Mahgoub ELhamaky, Benha University
A prospective study was performed on 8 eyes of 8 patients who underwent amniotic membrane graft after diffuse conjunctival squamous cell neoplasia excision followed by topical mitomycin C 0.04% eye drop between March 2014 and January 2018.
|Condition or disease||Intervention/treatment|
|Conjunctival Neoplasms||Procedure: Treatment of diffuse ocular surface squamous neoplasia|
Surgical excision of the conjunctival tumour . A superficial corneal scraping was performed for corneal lesion then double freeze-thaw cryotherapy was applied to limbal edge and conjunctival margins.The amniotic membrane graft was secure and attached to the sclera and conjunctiva using ﬁbrin glue.Topical mitomycin C 0.04%eye drop was prescribed 4 times daily per treatment cycle (1 cycle=1 week on 1 week off).
|Study Type :||Observational|
|Actual Enrollment :||15 participants|
|Official Title:||Anterior Segment Optical Coherence Tomography (AS-OCT) Guided Treatment of Diffuse Conjunctival Squamous Cell Carcinoma (CSCC) With Excision, Amniotic Membrane Graft Using Fibrin Glue and Topical Mitomycin C (MMC)|
|Actual Study Start Date :||March 2014|
|Actual Primary Completion Date :||January 2018|
|Actual Study Completion Date :||October 2018|
- Procedure: Treatment of diffuse ocular surface squamous neoplasia
Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.
Primary Outcome Measures :
- The recurrence rate of lesion [ Time Frame: 2 years ]Any recurrence which is detected clinically or/and by AS-OCT
No Contacts or Locations Provided